BMS-754807

For research use only.

Catalog No.S1124

27 publications

BMS-754807 Chemical Structure

CAS No. 1001350-96-4

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Size Price Stock Quantity  
USD 180 In stock
USD 270 In stock
USD 770 In stock
USD 2070 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's BMS-754807 has been cited by 27 publications

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.
Features Muti-inhibitor of the IGR-1R/IR family.
Targets
Insulin Receptor [1]
(Cell-free assay)
IGF-1R [1]
(Cell-free assay)
TrkB [1]
(Cell-free assay)
Met [1]
(Cell-free assay)
TrkA [1]
(Cell-free assay)
1.7 nM 1.8 nM 4.1 nM 5.6 nM 7.4 nM
In vitro

BMS-754807 effectively inhibits the growth of a broad range of human tumor cell lines of different histologic origins including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, and gastric), and hematopoietic (multiple myeloma and leukemia), the IC50 values range from 5 nM to 365 nM for the most sensitive cell lines. BMS-754807 inhibits proliferation of IGF-1R-Sal cells and RH41 cells with IC50 of 7 nM and 5 nM. BMS-754807 inhibits phosphorylation of IGF-1R in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 13 nM, 6 nM and 21 nM. BMS-754807 inhibits phosphorylation of Akt in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 22 nM, 13 nM and 16 nM. BMS-754807 induces greater apoptosis in Rh41 cells by 24 hours as indicated by an increased sub-G1 peak (23.1%), compared with control (2.4%). [1] BMS-754807 inhibits the phosphorylation of IGF-1R (IC50 = 13nM) and the downstream targets Akt (IC50 = 22nM) and MAPK (IC50 = 13nM) in the IGF-Sal cell line with IC50 consistent with the antiproliferative IC50 (7 nM) in this cell line. The crystal structure of BMS-754807 cocrystallized with the kinase domain of IGF-1R shows that the donor/acceptor/donor hydrogen bond triad with Met1052 and Glu1050 within the hinge region of the kinase. [2] BMS-754807 shows a median EC50 value of 0.62 μM against 23 cell lines in the pediatric preclinical testing program (PPTP). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
IGF-Sal M4DoU2tqdmG|ZTDhd5NigQ>? NGK2SJZqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFnHSk0yWiBqSVO1NEA:KDF|bl2pJIFv\CC2aHWg[I94dnO2cnXhcUB1[XKpZYTzJGFsfCBqSVO1NEA:KDJ{bl2pJIFv\CCPQWDLJEhKSzVyIE2gNVNvVSl? MVOxPVc4QDB{NB?=
IGF-Sal M2iyOmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MnO3TWM2OD15IH7N NXf1VlJCOTl5N{iwNlQ>
CCRF-CEM (ALL) M4e3RWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NGi1OpB,PSEQvF2= M{mwOGROW09? M{nnSWlEPTB;MT6yN|kh|ryP Mne0NVk6QTZ{N{K=
PC3 MljES5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVP+OUDPxE1? MXHEUXNQ NFP3dWpKSzVyPUCuPVY2KM7:TR?= NFy2VXMyQTl7NkK3Ni=>
JD M4fG[Wdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MmjGglUh|ryP NWKyXJd6TE2VTx?= MWPJR|UxRTBwM{mxJO69VQ>? M1fLWVE6QTl4Mkey
DU145 Mof4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M2PMWp42KM7:TR?= MWXEUXNQ MkexTWM2OD1zLkS2OUDPxE1? MUOxPVk6PjJ5Mh?=
KAG MlXFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3fiZ542KM7:TR?= MYTEUXNQ MXLJR|UxRTFwNk[1JO69VQ>? NGiweJYyQTl7NkK3Ni=>
K-562 (CML) MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NULxb2IyhjVizszN NIryV4FFVVOR Mm\iTWM2OD1{LkOwNkDPxE1? NYewSJhKOTl7OU[yO|I>
B6-P210 (Murine ALL) NYexeXFNT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MnXuglUh|ryP MXXEUXNQ NGDzZ5hKSzVyPUGuNlk{KM7:TR?= MoD1NVk6QTZ{N{K=
LN CAP-FGC NHXoSWxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M17OXZ42KM7:TR?= NVzrPYRYTE2VTx?= NWKySlMxUUN3ME2xMlQ{PCEQvF2= NEXVSnkyQTl7NkK3Ni=>
VW NEHjbGhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MoLtglUh|ryP NV;qfmRUTE2VTx?= NXTyWYRUUUN3ME2wMlAyQSEQvF2= MmLPNVk6QTZ{N{K=
MV411 (B Myelomonocytic) NWWyfoVYT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NGnIdZR,PSEQvF2= NGnkOpJFVVOR NEi5PIZKSzVyPUCuN|Mh|ryP NIKw[mQyQTl7NkK3Ni=>
MDA-PCa-2b MmL2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MlnCglUh|ryP NUDjUmFJTE2VTx?= NWr2OXE3UUN3ME2wMlA6QCEQvF2= NYnucJRyOTl7OU[yO|I>
LG M4i3dGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NIDESHJ,PSEQvF2= M4j2dmROW09? MW\JR|UxRTBwMEO4JO69VQ>? NU\mWoY1OTl7OU[yO|I>
RS411 (B cell precursor-ALL) NHixfGxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NUG3[llnhjVizszN M4D0WGROW09? MkfxTWM2OD1yLkGwNkDPxE1? MXWxPVk6PjJ5Mh?=
22-r-1 MnnVS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MoW0glUh|ryP NGrOfGZFVVOR MXTJR|UxRTBwMUe1JO69VQ>? MlHlNVk6QTZ{N{K=
5838 MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXO2blMxhjVizszN M1TFeWROW09? MmfsTWM2OD1yLkCzOEDPxE1? NFTl[moyQTl7NkK3Ni=>
P388 (Murine) NWH6Vpc3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MX3+OUDPxE1? NUDvSJVLTE2VTx?= M1rTO2lEPTB;ND6yO{DPxE1? NHPhfVIyQTl7NkK3Ni=>
A2780/S M13mN2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NIXKemZ,PSEQvF2= NYrFV|cyTE2VTx?= MXzJR|UxRTBwMUKyJO69VQ>? NYX2VGJ5OTl7OU[yO|I>
RDES MmPHS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NH3USIN,PSEQvF2= NV[0T3E5TE2VTx?= NGrWNnNKSzVyPUCuNFEzKM7:TR?= NYi2SWtROTl7OU[yO|I>
B6-T315I (Murine B-ALL) Mof6S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NF3ObIN,PSEQvF2= NFLUU21FVVOR NILBSGlKSzVyPUKuPFMh|ryP MorjNVk6QTZ{N{K=
TOV 112D Mkj6S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1nNTp42KM7:TR?= MkP3SG1UVw>? MXrJR|UxRTJwMUS2JO69VQ>? NHrWS5MyQTl7NkK3Ni=>
TC32 NV7ERVlrT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NEHkcWp,PSEQvF2= NW\EUGVZTE2VTx?= MWnJR|UxRTBwMEC4JO69VQ>? M{nwSlE6QTl4Mkey
HL60 (acute myelocytic) NWPs[JlrT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3T3Rp42KM7:TR?= M2\LeWROW09? NW\3[npvUUN3ME2wMlEzKM7:TR?= MXexPVk6PjJ5Mh?=
TOV 21G MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MlmyglUh|ryP NH;leFJFVVOR MYHJR|UxRTRwMke5JO69VQ>? MoLTNVk6QTZ{N{K=
TC71 MXfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVLQU4dlhjVizszN NUPtRol3TE2VTx?= M1rE[GlEPTB;MD6wNVQh|ryP M{j3TFE6QTl4Mkey
HPN-ALL (T-cell) M{XkSmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NE[yepl,PSEQvF2= NWe2SYs6TE2VTx?= M1XqVGlEPTB;MD61NkDPxE1? M333R|E6QTl4Mkey
A2780R NXK3O4J7T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MmnPglUh|ryP NXvQ[FltTE2VTx?= Mlm4TWM2OD1zLkW2OEDPxE1? NHzTVlAyQTl7NkK3Ni=>
Rh1 MVLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MkSyglUh|ryP MlnCSG1UVw>? NVTxc25XUUN3ME2wMlAzPyEQvF2= M1\KOFE6QTl4Mkey
Kasumi-1 (acute myeloid) Ml\RS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MUj+OUDPxE1? MU\EUXNQ NHHZWo5KSzVyPUCuNVYh|ryP MmW0NVk6QTZ{N{K=
sk-ov-3 MVjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIHpeoN,PSEQvF2= NXvkZ|BqTE2VTx?= M37uT2lEPTB;NT6xJO69VQ>? NWi0SZBROTl7OU[yO|I>
ME M{TlRWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NH;2V4J,PSEQvF2= Mn7rSG1UVw>? MlnZTWM2OD1yLkCxOUDPxE1? M4fRelE6QTl4Mkey
L1210 (Murine lymphocytic) MnXFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MW\+OUDPxE1? MWjEUXNQ MoToTWM2OD1{LkO5JO69VQ>? M2DCfVE6QTl4Mkey
sw-626 NUexVpFwT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NH3UUYd,PSEQvF2= NGnCVFdFVVOR NHzt[G1KSzVyPUKuN|A3KM7:TR?= MlTtNVk6QTZ{N{K=
CTR NEfpVFZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3;Nb542KM7:TR?= MkXPSG1UVw>? NHfhbI9KSzVyPUCuNlU{KM7:TR?= NEW2TIwyQTl7NkK3Ni=>
ML2 (Myelomonocytic) M2TO[Wdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MmDBglUh|ryP NIWyOlhFVVOR M{PrXWlEPTB;MD6wPUDPxE1? MlnyNVk6QTZ{N{K=
ovcar-3 NX[wfo5RT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MXj+OUDPxE1? MorjSG1UVw>? NVzUb3JDUUN3ME21JO69VQ>? NVTnXmp4OTl7OU[yO|I>
Rh36 MYLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mn;RglUh|ryP NU\DXZlLTE2VTx?= NIDMV45KSzVyPUGuOFMzKM7:TR?= MkTMNVk6QTZ{N{K=
MOLM-13 (acute myeloid) M2W2Xmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NI\5V|R,PSEQvF2= M3Wx[mROW09? M2nyb2lEPTB;MD60NkDPxE1? MmDBNVk6QTZ{N{K=
ovcar-4 NI\HWGJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NWf6PVNuhjVizszN MmiwSG1UVw>? NYDjc|V2UUN3ME2xJO69VQ>? MnP5NVk6QTZ{N{K=
Rh41 MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXvCdGRmhjVizszN MXrEUXNQ MVnJR|UxRTBwMEC1JO69VQ>? MVOxPVk6PjJ5Mh?=
Mutz 2 (acute myeloid) MmTsS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MlXlglUh|ryP MlnxSG1UVw>? M3nKVGlEPTB;MT6xOUDPxE1? NVjaWpEyOTl7OU[yO|I>
ovcar-5 M{j5Z2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NH3wfVJ,PSEQvF2= NWLGcm52TE2VTx?= MWnJR|UxRTBwMEWg{txO MXuxPVk6PjJ5Mh?=
RD1 NETmZZBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M{e4ep42KM7:TR?= NXnic5l7TE2VTx?= NX\tZZkzUUN3ME2wMlA3QCEQvF2= NYHYem4xOTl7OU[yO|I>
OCI-AML 2 (acute myeloid) M1\lVmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NULKeodphjVizszN MlrRSG1UVw>? NFjNdmpKSzVyPUOuN|Mh|ryP NHjGRZYyQTl7NkK3Ni=>
786-O NWX0V2x7T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= Mn;GglUh|ryP MUXEUXNQ M2rNR2lEPTB;MT62OFch|ryP MlvTNVk6QTZ{N{K=
A673 NV\leFd4T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NELLXZh,PSEQvF2= M33KbWROW09? NVfNc|VOUUN3ME2wMlQxQCEQvF2= NXnu[WN6OTl7OU[yO|I>
TALL-1 (T-cell) NHHBNoxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MV7+OUDPxE1? MX7EUXNQ M4nHdmlEPTB;MT6yPEDPxE1? NHrTd4cyQTl7NkK3Ni=>
151-B NXL5U3FFT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NXuwToVrhjVizszN NEmxPJlFVVOR M4q2fWlEPTB;Mj62O{DPxE1? M1;TN|E6QTl4Mkey
PFSK-1 NUf2RXNST3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4n0N542KM7:TR?= NILCUmpFVVOR MV7JR|UxRTBwMUOyJO69VQ>? MnTGNVk6QTZ{N{K=
THP-1 NF24[IRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MonTglUh|ryP NXLYdWdwTE2VTx?= NYDlWJY3UUN3ME22MlU5KM7:TR?= MmS2NVk6QTZ{N{K=
HEK293 NWfSSmhCT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NHXacXl,PSEQvF2= NVWxZnpVTE2VTx?= MXTJR|UxRTBwOUG1JO69VQ>? M{XtNVE6QTl4Mkey
DAOY NFna[HlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M1fOZp42KM7:TR?= M3jZdWROW09? NGrvelJKSzVyPUGuPVc6KM7:TR?= NGm2bmsyQTl7NkK3Ni=>
SET2 MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M4fTNZ42KM7:TR?= M4TkUGROW09? NVTMbHlLUUN3ME2wMlI6QCEQvF2= MXqxPVk6PjJ5Mh?=
HTB-46 M4TsV2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M3H0PJ42KM7:TR?= M2rKXGROW09? MlnITWM2OD13LkK1JO69VQ>? NGfrd4gyQTl7NkK3Ni=>
SK-NAS M4\Tdmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MkXBglUh|ryP M4LvVmROW09? M1rRbmlEPTB;MD60PVch|ryP MUGxPVk6PjJ5Mh?=
CTLL2 NI\PUVlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NXjCVHl4hjVizszN MkHsSG1UVw>? NHXIOXhKSzVyPkGuNFAh|ryP NFu0WpIyQTl7NkK3Ni=>
HTB-47 MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NHKzTHN,PSEQvF2= MoPXSG1UVw>? NGTDc21KSzVyPUKuNFU3KM7:TR?= NVO3[24yOTl7OU[yO|I>
LAN-1 MWnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGnlbnh,PSEQvF2= MVHEUXNQ NUD6RW5QUUN3ME2wMlA1KM7:TR?= MkjuNVk6QTZ{N{K=
ST486 MnXrS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVj+OUDPxE1? NEX2ZYJFVVOR M3vWTmlEPTB;MT6xPUDPxE1? NXXE[3VKOTl7OU[yO|I>
HS766T MoLFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MUP+OUDPxE1? NYL0[VA6TE2VTx?= MYXJR|UxRTJwMECxJO69VQ>? MXuxPVk6PjJ5Mh?=
IMR-32 MWjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIXLW2F,PSEQvF2= M4T2ZmROW09? NHrXOZRKSzVyPUCuNlYyKM7:TR?= NWDM[WVVOTl7OU[yO|I>
Daudi (Burkitt's) NFHM[mNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MX\+OUDPxE1? M{\MUWROW09? NYrvbJdYUUN3ME2yMlY{PyEQvF2= MnzzNVk6QTZ{N{K=
Aspc-1 MVzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXTnU5VyhjVizszN MYLEUXNQ MmK5TWM2OD1yLkO3PUDPxE1? NGrvXHoyQTl7NkK3Ni=>
SK-NSH MYLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MnHEglUh|ryP NEXldJRFVVOR NFrZdmNKSzVyPUCuNVM6KM7:TR?= MkjPNVk6QTZ{N{K=
MEC-1 (Chronic B cell) M4HSV2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVjib4NFhjVizszN NWL1bZlvTE2VTx?= NX63ZYZjUUN3ME2yMlY{PyEQvF2= M1TGcFE6QTl4Mkey
Capan-2 NIrNeJhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MoTWglUh|ryP M{TCZmROW09? MWDJR|UxRTFwN{e0JO69VQ>? NUe2UIN5OTl7OU[yO|I>
SHSY5Y NYO5[WdkT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MYr+OUDPxE1? MUHEUXNQ NHL5cVhKSzVyPUCuNVA3KM7:TR?= MVKxPVk6PjJ5Mh?=
U937 (Histioocytic) NV65e3p{T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFjmeJh,PSEQvF2= M2q2RmROW09? M4nsW2lEPTB-NT6wNEDPxE1? MVmxPVk6PjJ5Mh?=
Bxpc-1 MYjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NV32VINWhjVizszN MXXEUXNQ NY\zTVB5UUN3ME2xMlkzPCEQvF2= MnPHNVk6QTZ{N{K=
Bxpc-3 MmPaS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVv+OUDPxE1? NGS3T|lFVVOR Mn7nTWM2OD53LkCwJO69VQ>? NFO2dJoyQTl7NkK3Ni=>
HTB-92 MXrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M1zrdJ42KM7:TR?= MmP5SG1UVw>? Ml3CTWM2OD1zLkCyJO69VQ>? M2LCb|E6QTl4Mkey
OCI-LY10 (B-cell) NEDTTVdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NFLQOGV,PSEQvF2= MWrEUXNQ M1nL[2lEPTB;MD60OUDPxE1? MVexPVk6PjJ5Mh?=
PANC-1 NIDEdoRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MYP+OUDPxE1? NYGzPYM6TE2VTx?= NGnWeZNKSzVyPkWuNFAh|ryP MX2xPVk6PjJ5Mh?=
To184.T M{fvSmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NEXyUmF,PSEQvF2= M13XSGROW09? NFv4dXVKSzVyPUCuOFY6KM7:TR?= NULSbJh3OTl7OU[yO|I>
OCI-LY19 (B-cell) NYr6b|NVT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NXu5[ZJ1hjVizszN MlTNSG1UVw>? NXj4OIdrUUN3ME2wMlQh|ryP NIXoV5oyQTl7NkK3Ni=>
PANC-1 BM MVLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MU\+OUDPxE1? NXrVPZFvTE2VTx?= NGfESYJKSzVyPkWuNFAh|ryP MlTxNVk6QTZ{N{K=
SA-4 MlzqS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MV\+OUDPxE1? MX\EUXNQ Ml3CTWM2OD1zLkOwNUDPxE1? MmjLNVk6QTZ{N{K=
RPMI 8226 M3\HWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MmT0glUh|ryP M2LPfGROW09? M3vMOGlEPTB;MT6yPVMh|ryP MUmxPVk6PjJ5Mh?=
HPAF-II MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXn+OUDPxE1? MXHEUXNQ MmjrTWM2OD1yLk[0OEDPxE1? NWnHOZZkOTl7OU[yO|I>
SHP-77 MmDXS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NYLucng1hjVizszN NGjDdppFVVOR M1;nPWlEPTB;MT64PFgh|ryP MUGxPVk6PjJ5Mh?=
U266 B1 MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NHLTW2p,PSEQvF2= MkXhSG1UVw>? MlXwTWM2OD1zLk[2PUDPxE1? M3TrSFE6QTl4Mkey
Hs700t NG\SVFJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MV7+OUDPxE1? MVrEUXNQ NET6XVlKSzVyPUCuNlMyKM7:TR?= NVTJc2tvOTl7OU[yO|I>
NCI-446 M1Gydmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mme2glUh|ryP M1\ZWGROW09? NESye5FKSzVyPUGuNVU1KM7:TR?= MnG0NVk6QTZ{N{K=
H929 MULHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFv1RWR,PSEQvF2= M1nTSWROW09? MmjiTWM2OD1yLkCxOEDPxE1? NGLseYEyQTl7NkK3Ni=>
PL45 M4H1Vmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MmS4glUh|ryP M{P5OmROW09? M{HnNmlEPTB;Mj6yOVUh|ryP NXTNRXhkOTl7OU[yO|I>
NCI-H383 MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NHfIT4p,PSEQvF2= NGDTcHZFVVOR NVTacJZCUUN3ME61MlAxKM7:TR?= NVjGSodzOTl7OU[yO|I>
JJN3 MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MUD+OUDPxE1? NGqzOJJFVVOR M3nsPGlEPTB;Mj60N|Mh|ryP M2ezRVE6QTl4Mkey
SU.86.86 Mny2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXvzOpVmhjVizszN MWDEUXNQ NWPuU5JOUUN3ME2yMlY4OiEQvF2= Mle2NVk6QTZ{N{K=
H1299 NFzNUYRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHL4OJp,PSEQvF2= MV7EUXNQ MmrUTWM2OD53LkCwJO69VQ>? NIHxS3IyQTl7NkK3Ni=>
MDA-MB-468 M4D4eWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MnLBglUh|ryP MWfEUXNQ NEjtOYNKSzVyPUCuOVA1KM7:TR?= M3;2flE6QTl4Mkey
SW1990 MnHpS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NYHZTZJlhjVizszN M3ftcmROW09? NWrzNodGUUN3ME2wMlgzPiEQvF2= NF;DXocyQTl7NkK3Ni=>
Calu-6 MWHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIDyWGN,PSEQvF2= NYTTcI5iTE2VTx?= NH7FTnRKSzVyPkWuNFAh|ryP NIDyc2YyQTl7NkK3Ni=>
MDA-MB-231 MYrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGnZSFd,PSEQvF2= NIPJSYxFVVOR NHrlb4dKSzVyPUGuOlQ5KM7:TR?= NFvCUoYyQTl7NkK3Ni=>
SW-684 MUfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MUj+OUDPxE1? MnvMSG1UVw>? MWnJR|UxRjVwMECg{txO MljHNVk6QTZ{N{K=
H209 M37xXGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWrMfpg{hjVizszN NGq4cllFVVOR NGrWZ|RKSzVyPUGuNVk{KM7:TR?= MlS5NVk6QTZ{N{K=
MDA-MB-231T MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MlzBglUh|ryP M17SXWROW09? MkTMTWM2OD53LkCwJO69VQ>? M4HjNlE6QTl4Mkey
HT1080/S NGH2OGFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MXP+OUDPxE1? NGPNWoJFVVOR NYTlW5REUUN3ME2wMlU{OSEQvF2= MXuxPVk6PjJ5Mh?=
H526 0.044 NHjiNWhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Mn;iglUh|ryP NEPETIlFVVOR M1zPNGlEPTB;MD6wOFQh|ryP NVi0c5I3OTl7OU[yO|I>
DU4475 2.431 MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGTCUnp,PSEQvF2= MkHJSG1UVw>? Mn7vTWM2OD1{LkSzNUDPxE1? M3fNR|E6QTl4Mkey
HCT116 MlrkS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NVW1[GN4hjVizszN NGD5RmNFVVOR MXHJR|UxRTBwOEWyJO69VQ>? NXHGdJFnOTl7OU[yO|I>
M109 Mk\uS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Mn\0glUh|ryP MXHEUXNQ NVfvTVVRUUN3ME2xMlA2PSEQvF2= M4Kxb|E6QTl4Mkey
BT549 M2DaT2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUP+OUDPxE1? M{HVTmROW09? MU\JR|UxRTFwNkS1JO69VQ>? NYDIZW5yOTl7OU[yO|I>
HCT116/VM46 Ml3CS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHrNT5V,PSEQvF2= Ml\vSG1UVw>? NYmx[m9HUUN3ME2xMlcxOiEQvF2= MlnTNVk6QTZ{N{K=
H460 MV;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGO1enN,PSEQvF2= MnvwSG1UVw>? MoPzTWM2OD1yLke5OUDPxE1? MXKxPVk6PjJ5Mh?=
MCF-7 MUXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MV;+OUDPxE1? NGe0ZnZFVVOR MnrnTWM2OD1yLkCxOkDPxE1? M1X1NFE6QTl4Mkey
GEO MWDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYPWTllQhjVizszN NGjZNYVFVVOR NFXndYJKSzVyPUCuN|U3KM7:TR?= NXXjZmsyOTl7OU[yO|I>
H441 0.646 NWTkS3M4T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVX+OUDPxE1? M1T6XWROW09? NGHZV49KSzVyPUCuOlQ3KM7:TR?= MYixPVk6PjJ5Mh?=
MCF-7-807R NF30[VVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M1vpN542KM7:TR?= NXPkdZBpTE2VTx?= NEnzXJZKSzVyPUCuOFkh|ryP M{PSVFE6QTl4Mkey
Colo205 MlHvS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NGHRSIN,PSEQvF2= NXjuW3JkTE2VTx?= MlLjTWM2OD1yLkGwOEDPxE1? MXOxPVk6PjJ5Mh?=
H292 NUTHU3dLT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYn0SYFuhjVizszN NIjC[5hFVVOR MoHhTWM2OD1yLke4PEDPxE1? MlHiNVk6QTZ{N{K=
BT474 (S) M3raT2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NHTRbJZ,PSEQvF2= NFvXVIdFVVOR MnqyTWM2OD1{LkSwN{DPxE1? M2XxNVE6QTl4Mkey
HT-29 NIiy[VNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MlX6glUh|ryP NWLscnZ5TE2VTx?= Ml3KTWM2OD1{LkGwN{DPxE1? M1W5e|E6QTl4Mkey
A549 NHS0fWRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NU\YUIpOhjVizszN NYDGTlRoTE2VTx?= MWjJR|UxRTBwNke1JO69VQ>? MnLINVk6QTZ{N{K=
BT474-M1 NUj4b|FuT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MmLjglUh|ryP Ml[3SG1UVw>? MX3JR|UxRTJwM{[1JO69VQ>? Mnm4NVk6QTZ{N{K=
SW480 NYjyOFlzT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NHm5VZd,PSEQvF2= M1\VfGROW09? MVvJR|UxRjVwMECg{txO M2r6OlE6QTl4Mkey
L2987 NWr3NYU1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NXfpcFRIhjVizszN MWLEUXNQ MXrJR|UxRTBwNESyJO69VQ>? NYHwNmd4OTl7OU[yO|I>
AU565 MV\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M4TuXp42KM7:TR?= MU\EUXNQ MlTaTWM2OD12Lkm3JO69VQ>? NXzIV2llOTl7OU[yO|I>
SW403 MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFrnXFN,PSEQvF2= MX3EUXNQ MknyTWM2OD1yLkKyJO69VQ>? M2HFPVE6QTl4Mkey
H1437 NIO0VItIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVf+OUDPxE1? MUPEUXNQ MU\JR|UxRTBwNUKzJO69VQ>? NGf6NmcyQTl7NkK3Ni=>
BT-20 NVPIT2MzT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVr+OUDPxE1? MkXzSG1UVw>? NXP1XpM4UUN3ME2zMlU3OiEQvF2= MV6xPVk6PjJ5Mh?=
Colo320HSR MUTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MWP+OUDPxE1? NFnkOnZFVVOR NETGNVJKSzVyPUCuNFEyKM7:TR?= NFTsc4EyQTl7NkK3Ni=>
H2087 MX;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFTjXXl,PSEQvF2= MY\EUXNQ M3XvU2lEPTB-MT6wNEDPxE1? MlLJNVk6QTZ{N{K=
HCC1419 M1LINGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1nYfZ42KM7:TR?= NXX4eJNzTE2VTx?= NHLEOHpKSzVyPUKuOVE4KM7:TR?= NFvqcFMyQTl7NkK3Ni=>
WiDr NWDtdWloT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MUL+OUDPxE1? MX;EUXNQ NXLFSHpvUUN3ME2wMlA4PiEQvF2= MWCxPVk6PjJ5Mh?=
H661 0.573 NFnMfIZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHfsVGx,PSEQvF2= MVrEUXNQ M{HwVGlEPTB;MD61O|Mh|ryP NUnPWIpVOTl7OU[yO|I>
HCC-38 NXrw[mlCT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4nmdZ42KM7:TR?= M1LIVmROW09? MVrJR|UxRjVwMECg{txO MkjqNVk6QTZ{N{K=
LS174T M1fQ[mdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MW\+OUDPxE1? NGLsd4FFVVOR MoLWTWM2OD1yLkWzOUDPxE1? M2rlTlE6QTl4Mkey
H211 MlPyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NUjSeXV5hjVizszN Mk\iSG1UVw>? NILTTFhKSzVyPUCuO|M{KM7:TR?= M1;Gd|E6QTl4Mkey
HCC70 NUK2cYZmT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MkXZglUh|ryP M{jKR2ROW09? NV;w[WV{UUN3ME2xMlU2KM7:TR?= MmrtNVk6QTZ{N{K=
SW116 MYHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mm\DglUh|ryP M3HNV2ROW09? MXTJR|UxRTBwME[3JO69VQ>? NXjBRWJ[OTl7OU[yO|I>
H513 M1XxSmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2DRXZ42KM7:TR?= M2PRXmROW09? M3zTV2lEPTB;ND60OFgh|ryP NH7vN3QyQTl7NkK3Ni=>
MDA-MB-157 M1npb2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NYnxPVU6hjVizszN NVrpcVhLTE2VTx?= M2K1[WlEPTB;MD6wN|Yh|ryP M2TFN|E6QTl4Mkey
H2052 MWHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M3viXJ42KM7:TR?= NYDuc2ZvTE2VTx?= NVLHdmNEUUN3ME2xMlA2KM7:TR?= NI\xO2EyQTl7NkK3Ni=>
MDA-MB-415 MXTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFvHc3J,PSEQvF2= NI\odotFVVOR NUCydol[UUN3ME61MlAxKM7:TR?= M2G2b|E6QTl4Mkey
DLD-1 MoDZS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MWX+OUDPxE1? NFLXWnRFVVOR MYDJR|UxRTBwOUC5JO69VQ>? M1zIRlE6QTl4Mkey
H2595 Ml7FS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MlHLglUh|ryP MmrHSG1UVw>? Mn\vTWM2OD12LkS3OUDPxE1? NFPNXW8yQTl7NkK3Ni=>
MDA-MB-435S NFjzd4JIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NWK0W4s2hjVizszN MVjEUXNQ MYHJR|UxRTFwOE[5JO69VQ>? Ml3uNVk6QTZ{N{K=
HCT15 MYnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGLqc4R,PSEQvF2= MX3EUXNQ M3vT[WlEPTB-MT6wNEDPxE1? Ml32NVk6QTZ{N{K=
SK-Hep1 M{Xzcmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NHKxT5V,PSEQvF2= NXrBUXRNTE2VTx?= NXHjVYkyUUN3ME2wMlE1PiEQvF2= NXe4S3I3OTl7OU[yO|I>
MDA-MB-436 M4i3bGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Ml7PglUh|ryP NX;lZXZUTE2VTx?= NXWxeVZpUUN3ME21MlUxOiEQvF2= MmTYNVk6QTZ{N{K=
KM12C NVvzcYhWT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MoL1glUh|ryP MXXEUXNQ MlzFTWM2OD1yLkC1OEDPxE1? M4DvNVE6QTl4Mkey
HEPG2 M{PJUGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NF64d3d,PSEQvF2= MWfEUXNQ MV;JR|UxRTBwMEK1JO69VQ>? M3zWb|E6QTl4Mkey
MDA-MB-453 NIT1b|NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NELCTI1,PSEQvF2= MVrEUXNQ NWTKb5ZyUUN3ME2xMlg3QSEQvF2= Mlq3NVk6QTZ{N{K=
KM12SM NYrjVo9DT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NGPDRWJ,PSEQvF2= NVK2WXRWTE2VTx?= NGP0W|JKSzVyPUCuNFU6KM7:TR?= NGfweZoyQTl7NkK3Ni=>
1483 NVzuVY03T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NGTuTVN,PSEQvF2= NVvkVm5xTE2VTx?= NWPOdWhUUUN3ME2yMlE6KM7:TR?= NVryPYU4OTl7OU[yO|I>
Hs578t NH72[3pIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Mni0glUh|ryP NUjyfWJUTE2VTx?= NGG2fpdKSzVyPUGuNlg4KM7:TR?= NFjVWnoyQTl7NkK3Ni=>
LS180 NVrSS4ZpT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVL+OUDPxE1? NHTwV|hFVVOR NHHnRYRKSzVyPUCuOlk3KM7:TR?= MXqxPVk6PjJ5Mh?=
FaDu M2r5O2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NYqzcZZThjVizszN NInieYxFVVOR M13Ob2lEPTB;MT6yO{DPxE1? M37IOlE6QTl4Mkey
ZR-75-1 M3O0Wmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXTMPYhWhjVizszN NGTkR2RFVVOR NX;JZpVYUUN3ME2yMlA5PCEQvF2= Mn71NVk6QTZ{N{K=
LS513 MnyyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXz4TFZJhjVizszN MnPBSG1UVw>? NYD2Wll6UUN3ME2wMlE{PSEQvF2= MUmxPVk6PjJ5Mh?=
Detroit.562 NFO3NoRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3Tzd542KM7:TR?= NUjRO5NxTE2VTx?= MofGTWM2OD1zLkG0JO69VQ>? M1PUU|E6QTl4Mkey
ZR-75-30 MnnLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MX;+OUDPxE1? M37sXGROW09? M2r4SmlEPTB-NT6wNEDPxE1? NFrzXWYyQTl7NkK3Ni=>
RKO-PM NWfTNGpuT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MnOxglUh|ryP NGHXdFJFVVOR M3;Sb2lEPTB;MD6yN|Ih|ryP M1fiTFE6QTl4Mkey
Cal.27 Mlj5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MWj+OUDPxE1? MWrEUXNQ M4PpWmlEPTB;MjFOwG0> NWLBWnZxOTl7OU[yO|I>
KPL4 NIGw[|NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3Tmcp42KM7:TR?= NFTie|BFVVOR NH7mZo1KSzVyPUGuNlUzKM7:TR?= MVuxPVk6PjJ5Mh?=
PKO-RM13 M4X4R2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MWL+OUDPxE1? MmjYSG1UVw>? MVfJR|UxRTBwNEK1JO69VQ>? NWDuZVhCOTl7OU[yO|I>
HS.53.T NInJZpBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MWn+OUDPxE1? MnLYSG1UVw>? NX;FNmFTUUN3ME2wMlc6KM7:TR?= MX:xPVk6PjJ5Mh?=
EMT6 MoPiS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NX[xR3VPhjVizszN MorFSG1UVw>? Mmj1TWM2OD1yLkiwOkDPxE1? NHL2UZYyQTl7NkK3Ni=>
SNU-C1 NFHn[VBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NGDWO5R,PSEQvF2= NWHWcFh5TE2VTx?= M2rNZ2lEPTB;MD6wNFch|ryP MUGxPVk6PjJ5Mh?=
SQCCY1 MmjrS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1mxfJ42KM7:TR?= MVPEUXNQ Mn3yTWM2OD1yLke5JO69VQ>? MV:xPVk6PjJ5Mh?=
SW480 NFnWdZlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Ml\aglUh|ryP MVTEUXNQ NIrzdVFKSzVyPUCuNFM4KM7:TR?= NULpRmlNOTl7OU[yO|I>
SCC9 MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MUX+OUDPxE1? MYnEUXNQ NVrlTGg6UUN3ME2wMlc2KM7:TR?= MVuxPVk6PjJ5Mh?=
SK-LMS-1 M3zBdWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M{fCRp42KM7:TR?= NV;pVlNKTE2VTx?= NFHvbFhKSzVyPUCuOlg4KM7:TR?= MlHHNVk6QTZ{N{K=
SCC25 MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mn7iglUh|ryP M2O1S2ROW09? NVfmT2VSUUN3ME2wMlY5KM7:TR?= Mlm1NVk6QTZ{N{K=
U87 NIi5bVNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M4PnPZ42KM7:TR?= MmfuSG1UVw>? M4TIWmlEPTB;MD65OUDPxE1? NI[wdpEyQTl7NkK3Ni=>
SCC15 M4H6c2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVjOV4VVhjVizszN MoHaSG1UVw>? NXvhe5lIUUN3ME2wMlY4KM7:TR?= NYfKUItzOTl7OU[yO|I>
T98G MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M3HLdZ42KM7:TR?= NV:1[o9iTE2VTx?= MWXJR|UxRTFwMkG4JO69VQ>? MUmxPVk6PjJ5Mh?=
SCC4 M2nQWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MWT+OUDPxE1? NGLIfIpFVVOR MmntTWM2OD1yLk[zJO69VQ>? NYHVfphPOTl7OU[yO|I>
U118 MorZS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFn4[Yx,PSEQvF2= MljWSG1UVw>? NXTqPJFRUUN3ME2xMlYyQCEQvF2= NFPiWIcyQTl7NkK3Ni=>
TU167 MmLtS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MXf+OUDPxE1? MmS4SG1UVw>? NH\ve2lKSzVyPUSuOVIh|ryP NELJbm0yQTl7NkK3Ni=>
NCI-H727 NVXHW4l7T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFjQfJV,OTEkgJtOwG0> MVHEUXNQ NV75TlJTUUN3ME20Nlghdk1? MYGyNFM5PTd2Nx?=
NCI-H720 MWPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mn\LglEx6oDMzszN M1Xj[WROW09? NIPtN49KSzVyPUKuPEDPxE1? MlG5NlA{QDV5NEe=
NCI-H835 NXPOb5JIT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MkjUglEx6oDMzszN MYnEUXNQ MWfJR|UxRTFizszN MlrqNlA{QDV5NEe=
NCI-H727 NInLUFdMcW6jc3WgZZN{[Xl? NHTkfZh,OTEkgJtOwG0> NVfa[WN1TE2VTx?= MYDpcohq[mm2czDjc45{fGm2dYTpeoUhUUeIMWKgZZV1d3Cqb4PwbI9zgWyjdHnvci=> MkLjNlA{QDV5NEe=
RD NULTSYw3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MnfOglEx6oDMzszN M3nnVWlEPTB;MT6xNkDDvU1? MnznNlEzQTh5NEW=
Rh41 NV75fHcyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MUL+NVDjiIsQvF2= MXTJR|UxRTBwMEegxtVO M{PNTFIyOjl6N{S1
Rh18 NWm4[GwyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1Lze54yOOLCit88US=> Mn;JTWM2OD12Lkm2JOK2VQ>? NUflO3JUOjF{OUi3OFU>
Rh30 M1y0Umdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NFTNWJR,OTEkgJtOwG0> NVfsV3drUUN3ME2wMlE6KML3TR?= MYmyNVI6QDd2NR?=
BT-12 MV3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MnruglEx6oDMzszN M2DoT2lEPTB;MD63PEDDvU1? MYOyNVI6QDd2NR?=
CHLA-266 M1P4Smdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MkG1glEx6oDMzszN MnPiTWM2OD1yLki5JOK2VQ>? NHXGWJgzOTJ7OEe0OS=>
TC-71 Ml3ZS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M4qweJ4yOOLCit88US=> NVK3UVlqUUN3ME2wMlEyKML3TR?= M{K1WVIyOjl6N{S1
CHLA-9 MXvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M1r5dJ4yOOLCit88US=> NUWxT5I6UUN3ME2wMlEzKML3TR?= M2\zWFIyOjl6N{S1
CHLA-10 M1K3dmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NV[0WGFDhjFy4pEK{txO M2izUWlEPTB;MD62NkDDvU1? MnzCNlEzQTh5NEW=
CHLA-258 NIPaNFFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVn+NVDjiIsQvF2= NGfBb45KSzVyPUCuNlchyrWP NX:yeZlKOjF{OUi3OFU>
GBM2 NFvw[mVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MW\+NVDjiIsQvF2= M{LqN2lEPTB;MT60O{DDvU1? M{fsW|IyOjl6N{S1
NB-1643 M3S3WWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NV71V3o1hjFy4pEK{txO MV3JR|UxRTBwMUKgxtVO MnXwNlEzQTh5NEW=
NB-EBc1 NEXMUGZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NF7Fdoh,OTEkgJtOwG0> NIXvfnVKSzVyPUCuN|UhyrWP MlTyNlEzQTh5NEW=
CHLA-90 NE\i[pVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NEPoTVd,OTEkgJtOwG0> MluyTWM2OD1yLke3JOK2VQ>? Ml3iNlEzQTh5NEW=
CHLA-136 M3n4W2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mn7qglEx6oDMzszN M1PrR2lEPTB;MD61NkDDvU1? NGPOV3MzOTJ7OEe0OS=>
NALM-6 NEfGc4JIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NWL5VI1NhjFy4pEK{txO NUHLWlBbUUN3ME2wMlQ6KML3TR?= NX\Q[G5JOjF{OUi3OFU>
COG-LL-317 NEPWZ49Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NV\5fmtKhjFy4pEK{txO MnzxTWM2OD1zLkO4JOK2VQ>? NGD2UYkzOTJ7OEe0OS=>
RS4;11 MYrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MkP3glEx6oDMzszN MVzJR|UxRTBwM{igxtVO NVrYOGU6OjF{OUi3OFU>
MOLT-4 NF;reJZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NIHCNFN,OTEkgJtOwG0> MYDJR|UxRTBwNUOgxtVO MnLnNlEzQTh5NEW=
CCRF-CEM MmDkS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVj+NVDjiIsQvF2= MV;JR|UxRTFwMUOgxtVO NHfkcHEzOTJ7OEe0OS=>
Kasumi-1 NGLlRpFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVz+NVDjiIsQvF2= MmLvTWM2OD1zLkKgxtVO MoLiNlEzQTh5NEW=
Karpas-299 M1TnUWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M4G4cZ4yOOLCit88US=> MoHLTWM2OD1zLk[0JOK2VQ>? M1TmZ|IyOjl6N{S1
Ramos-RA1 M{LxRmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVnmb4pNhjFy4pEK{txO Mmr6TWM2OD1zLkOxJOK2VQ>? NUjwO4l7OjF{OUi3OFU>
Rh30  M3zqbWZ2dmO2aX;uJIF{e2G7 NWe2dWw{cW6mdXPld{BidiCrbnPy[YF{\SCxZjDTSmsheGixc4Doc5J6dGG2aX;u MUSyOVkzPTN5OB?=
Rh41 NHT4ZVdHfW6ldHnvckBie3OjeR?= NUftVmRScW6mdXPld{BidiCrbnPy[YF{\SCxZjDTSmsheGixc4Doc5J6dGG2aX;u Mlu2NlU6OjV|N{i=
RD NYTVRYJbTnWwY4Tpc44h[XO|YYm= NV3wPWlTcW6mdXPld{BidiCrbnPy[YF{\SCxZjDTSmsheGixc4Doc5J6dGG2aX;u M3vvWlI2QTJ3M{e4
A549 MnnQT4lv[XOnIHHzd4F6 NFr1N5YxNjYkgJtOwG0> MmS0SG1UVw>? NHXtcW1qdmirYnn0d{BKT0ZvSWKvTXIh[WO2aY\heIlwdg>? NVXBUFVxOjZ7Mki1O|g>
NCI-H358 NUjESZJ3U2mwYYPlJIF{e2G7 NXLvVIlVOC534pEK{txO MlfwSG1UVw>? NULtUnZVcW6qaXLpeJMhUUeILVnSM2lTKGGldHn2ZZRqd25? NHHITGwzPjl{OEW3PC=>
A549 M4jHTGZ2dmO2aX;uJIF{e2G7 MlPDNE426oDMzszN Mn;CSG1UVw>? MV\jZZV{\XNiYTDjc45kfXK{ZX70JIRm[3KnYYPlJIlvKHCqb4PwbI9zgWyjdHXkJGFMXCCjbnSgSXJM M17GVVI3QTJ6NUe4
NCI-H358 NH3KS4ZHfW6ldHnvckBie3OjeR?= NWnIVnl7OC534pEK{txO MW\EUXNQ NVvXW2E6[2G3c3XzJIEh[2:wY4XydoVvfCCmZXPy[YF{\SCrbjDwbI9{eGixconsZZRm\CCDS2SgZY5lKEWUSx?= NVHPTId5OjZ7Mki1O|g>
A549 MYHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFvXXHR,OTEkgJtOwG0> NXrDe4c3TE2VTx?= Ml\hTWM2OD1yLke2JO69VQ>? NWrXfWVCOjZ7Mki1O|g>
NCI-H358 MnH3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFT2OnB,OTEkgJtOwG0> MYPEUXNQ M1ewR2lEPTB;MT6wPUDPxE1? M3zJUlI3QTJ6NUe4
A549 NY\RPW5xSXCxcITvd4l{KGG|c3H5 NHTpZo4xNjYkgJtOwG0> M4T6[GROW09? NGTGeWdqdmS3Y3XzJGFxd3C2b4Ppdy=> NWP0S5REOjZ7Mki1O|g>
NCI-H358 NEn6XXpCeG:ydH;zbZMh[XO|YYm= Mk\BNE426oDMzszN M13ZeGROW09? NVzZSlB7cW6mdXPld{BCeG:ydH;zbZM> NX\KbY1[OjZ7Mki1O|g>
A549 NHXBV5VHfW6ldHnvckBie3OjeR?= MlvGNE426oDMzszN MUXEUXNQ MU\y[YR2[2W|IIfveY5lKGOub4P1doU> NGjpTo0zPjl{OEW3PC=>
NCI-H358 M37sOWZ2dmO2aX;uJIF{e2G7 NFmzZ2sxNjYkgJtOwG0> NEXwSnlFVVOR M4\OSJJm\HWlZYOge492dmRiY3zvd5Vz\Q>? MoX4NlY6Ojh3N{i=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-IGFIRRβ/InsRβ / IGFIRβ / p-AKT / AKT / p-ERK / ERK ; 

PubMed: 26136493     


(C) T4105 cells were treated with OSI-906 or BMS-754807 at indicated concentrations for 24 hours, lysed, and subjected to immunoblotting.

26136493
Growth inhibition assay
Cell viability; 

PubMed: 30754629     


Response of SK-CO-1 to various drugs and drug combinations.

30754629
In vivo BMS-754807 (12.5mg/kg, orally) inhibits IGF-1R phosphorylation in tumor and serum in IGF-1R-Sal tumor–bearing nude mice. BMS-754807 inhibits tumor growth in a selected group of epithelial (IGF-1R-Sal, GEO, and Colo205), hematopoietic (JJN3), and mesenchymal (RD1 and Rh41) xenograft tumor models with TGI ranging from 53% to 115%. [1] BMS-754807 (6.25 mg/kg) achieves complete tumor growth inhibition in the transgenic-derived IGF-Sal tumor mouse model with correlated inhibition of pIGF-1R and pAKT. The protein binding for BMS-754807 ranges from of 98.5% in mouse plasma to 95.9% in human plasma. BMS-754807 results in clearance of 113 (mL/min)/kg, 20 (mL/min)/kg, 3.5 (mL/min)/kg and 41 (mL/min)/kg. [2] BMS-754807 (25 mg/kg) significantly inhibits tumor in KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), and OS-1 xenografts mice model. [3]

Protocol

Kinase Assay:[1]
- Collapse

Kinase inhibition assays:

The primary screen for BMS-754807 is an in vitro kinase assay using recombinant human IGF-1 receptor enzyme in biochemical assays using synthetic peptide KKSRGDYMTMQIG as a phosphoacceptor substrate. The selectivity profile is evaluated against multiple recombinant enzymes that are generated at BMS or purchased externally. The enzymatic assays are performed in Ubottom 384-well plates using a 30 μL reaction volume in assay buffer (100 mM Hepes pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT). The 60 minute reactions are initiated by combining ATP (concentration equivalent to Km ATP), 1.5 μM fluoresceinlabeled peptide substrate, enzyme and BMS-754807. The reactions are terminated with EDTA. The reaction mixtures are analyzed on the Caliper LabChip 3000 by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data are calculated by comparison to enzyme-free control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. Compounds are dissolved in dimethylsulfoxide (DMSO, 10mM stock) and evaluated at eleven concentrations. IC50 values are derived by non-linear regression analysis of the dose response curves.
Cell Research:[1]
- Collapse
  • Cell lines: IGF-1R-Sal, RH41 and Geo cell lines
  • Concentrations: 365 nM
  • Incubation Time: 72 hours
  • Method: Cells are grown at their optimal density in RPMI +GlutaMax supplemented with 10% heat-inactivated fetal bovine serum (FBS), 10 mM Hepes, penicillin, and streptomycin. Cell proliferation is evaluated by incorporation of 3H-thymidine into DNA after exposure of cells to BMS-754807 for 72 hours. Results are expressed as an IC50, which is the drug concentration required to inhibit cell proliferation by 50% compared with untreated control cells.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: IGF-1R-Sal, GEO, Colo205, JJN3, RD1 or Rh41 tumor–bearing nude mice
  • Dosages: 150 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 92 mg/mL (199.35 mM)
Ethanol 92 mg/mL (199.35 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 461.49
Formula

C23H24FN9O

CAS No. 1001350-96-4
Storage powder
in solvent
Synonyms N/A
Smiles CC1(CCCN1C2=NN3C=CC=C3C(=N2)NC4=NNC(=C4)C5CC5)C(=O)NC6=CN=C(C=C6)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy BMS-754807|BMS-754807 ic50|BMS-754807 price|BMS-754807 cost|BMS-754807 solubility dmso|BMS-754807 purchase|BMS-754807 manufacturer|BMS-754807 research buy|BMS-754807 order|BMS-754807 mouse|BMS-754807 chemical structure|BMS-754807 mw|BMS-754807 molecular weight|BMS-754807 datasheet|BMS-754807 supplier|BMS-754807 in vitro|BMS-754807 cell line|BMS-754807 concentration|BMS-754807 nmr|BMS-754807 in vivo|BMS-754807 clinical trial|BMS-754807 inhibitor|BMS-754807 Protein Tyrosine Kinase inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID